aTyr Pharma (NASDAQ:ATYR – Get Free Report) and Silo Pharma (NASDAQ:SILO – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, profitability and earnings.
Earnings & Valuation
This table compares aTyr Pharma and Silo Pharma”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| aTyr Pharma | $190,000.00 | 439.06 | -$74.12 million | ($0.79) | -1.08 |
| Silo Pharma | $70,000.00 | 69.62 | -$4.23 million | ($0.54) | -0.64 |
Institutional & Insider Ownership
61.7% of aTyr Pharma shares are owned by institutional investors. Comparatively, 5.6% of Silo Pharma shares are owned by institutional investors. 3.7% of aTyr Pharma shares are owned by insiders. Comparatively, 2.2% of Silo Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Volatility and Risk
aTyr Pharma has a beta of 0.64, indicating that its stock price is 36% less volatile than the S&P 500. Comparatively, Silo Pharma has a beta of 0.35, indicating that its stock price is 65% less volatile than the S&P 500.
Profitability
This table compares aTyr Pharma and Silo Pharma’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| aTyr Pharma | N/A | -99.87% | -74.41% |
| Silo Pharma | -5,870.83% | -83.53% | -63.70% |
Analyst Ratings
This is a summary of recent ratings and price targets for aTyr Pharma and Silo Pharma, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| aTyr Pharma | 1 | 5 | 1 | 0 | 2.00 |
| Silo Pharma | 1 | 0 | 0 | 0 | 1.00 |
aTyr Pharma presently has a consensus target price of $25.67, suggesting a potential upside of 2,916.77%. Given aTyr Pharma’s stronger consensus rating and higher possible upside, research analysts plainly believe aTyr Pharma is more favorable than Silo Pharma.
Summary
aTyr Pharma beats Silo Pharma on 9 of the 14 factors compared between the two stocks.
About aTyr Pharma
aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.
About Silo Pharma
Silo Pharma Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations and drug delivery systems. The company’s lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. It is also developing SP-26, a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. In addition, the company’s two preclinical programs comprise SPC-14, an intranasal compound for the treatment of Alzheimer’s disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS). The company’s research and development programs are conducted through collaborations with Columbia University and the University of Maryland, Baltimore. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is based in Sarasota, Florida.
Receive News & Ratings for aTyr Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
